Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on ‘big things’ in M&A — analyst
Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on ‘big things’ in M&A — analyst
Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on ‘big things’ in M&A — analyst
Submitted by
admin
on February 2, 2018 - 9:31am
Source:
Endpoints
News Tags:
Amgen
tax reform
M&A
Headline:
Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on ‘big things’ in M&A — analyst
Do Not Allow Advertisers to Use My Personal information